Have your own idea? Try our Stock Screener
Chinese (SSE) Clinical Research and Equipment Industry Analysis
UpdatedJul 15, 2025
DataAggregated Company Financials
Companies27
- 7D10.3%
- 3M32.7%
- 1Y72.2%
- YTDn/a
The Clinical Research and Equipment industry is up 10% in the last week, with WuXi AppTec up 14%. During this same period, the Improve Medical Instruments underperformed, falling 8.6%. This means that the industry has gained 72% over the past year. As for the next few years, earnings are expected to grow by 27% per annum.
Industry Valuation and Performance
Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 15 Jul 2025 | CN¥494.7b | CN¥89.8b | CN¥15.4b | 54x | 32.2x | 5.5x |
| Thu, 12 Jun 2025 | CN¥434.6b | CN¥89.8b | CN¥15.4b | 48.8x | 28.3x | 4.8x |
| Sat, 10 May 2025 | CN¥388.4b | CN¥89.2b | CN¥15.0b | 45.2x | 25.8x | 4.4x |
| Mon, 07 Apr 2025 | CN¥425.4b | CN¥88.5b | CN¥14.0b | 43.5x | 30.3x | 4.8x |
| Wed, 05 Mar 2025 | CN¥429.1b | CN¥89.0b | CN¥11.3b | 44.4x | 37.8x | 4.8x |
| Fri, 31 Jan 2025 | CN¥358.6b | CN¥88.1b | CN¥11.2b | 37.6x | 31.9x | 4.1x |
| Sun, 29 Dec 2024 | CN¥367.3b | CN¥87.8b | CN¥11.2b | 38.4x | 32.8x | 4.2x |
| Tue, 26 Nov 2024 | CN¥359.8b | CN¥87.8b | CN¥11.2b | 37.8x | 32.2x | 4.1x |
| Thu, 24 Oct 2024 | CN¥375.1b | CN¥88.2b | CN¥12.4b | 33.8x | 30.3x | 4.3x |
| Sat, 21 Sep 2024 | CN¥284.5b | CN¥88.2b | CN¥12.4b | 26.8x | 23x | 3.2x |
| Mon, 19 Aug 2024 | CN¥286.8b | CN¥87.7b | CN¥12.6b | 26.3x | 22.8x | 3.3x |
| Wed, 17 Jul 2024 | CN¥274.1b | CN¥88.3b | CN¥13.4b | 24.4x | 20.5x | 3.1x |
| Fri, 14 Jun 2024 | CN¥317.5b | CN¥88.3b | CN¥13.4b | 28x | 23.7x | 3.6x |
| Sun, 12 May 2024 | CN¥337.5b | CN¥88.3b | CN¥13.3b | 30.5x | 25.3x | 3.8x |
| Tue, 09 Apr 2024 | CN¥329.9b | CN¥90.3b | CN¥15.0b | 32.4x | 22x | 3.7x |
| Thu, 07 Mar 2024 | CN¥377.5b | CN¥90.5b | CN¥15.5b | 33x | 24.3x | 4.2x |
| Sat, 03 Feb 2024 | CN¥325.6b | CN¥91.1b | CN¥16.1b | 29.5x | 20.3x | 3.6x |
| Mon, 01 Jan 2024 | CN¥475.6b | CN¥91.1b | CN¥16.1b | 39.4x | 29.6x | 5.2x |
| Wed, 29 Nov 2023 | CN¥539.2b | CN¥91.1b | CN¥16.1b | 38.3x | 33.5x | 5.9x |
| Fri, 27 Oct 2023 | CN¥500.3b | CN¥92.2b | CN¥18.4b | 33.1x | 27.2x | 5.4x |
| Sun, 24 Sep 2023 | CN¥488.4b | CN¥92.0b | CN¥18.3b | 32.1x | 26.6x | 5.3x |
| Tue, 22 Aug 2023 | CN¥484.1b | CN¥91.6b | CN¥18.6b | 33.4x | 26.1x | 5.3x |
| Thu, 20 Jul 2023 | CN¥459.9b | CN¥91.3b | CN¥18.5b | 34.2x | 24.9x | 5x |
| Sat, 17 Jun 2023 | CN¥501.6b | CN¥91.3b | CN¥18.5b | 37.7x | 27.2x | 5.5x |
| Mon, 15 May 2023 | CN¥494.6b | CN¥91.3b | CN¥18.4b | 38.6x | 26.9x | 5.4x |
| Wed, 12 Apr 2023 | CN¥588.0b | CN¥91.2b | CN¥19.1b | 53.1x | 30.8x | 6.5x |
| Fri, 10 Mar 2023 | CN¥594.1b | CN¥85.5b | CN¥20.0b | 51.9x | 29.7x | 6.9x |
| Sun, 05 Feb 2023 | CN¥684.0b | CN¥86.6b | CN¥20.8b | 58.3x | 32.9x | 7.9x |
| Tue, 03 Jan 2023 | CN¥603.9b | CN¥86.6b | CN¥20.8b | 50.9x | 29x | 7x |
| Thu, 01 Dec 2022 | CN¥587.2b | CN¥86.6b | CN¥20.8b | 49.6x | 28.2x | 6.8x |
| Sat, 29 Oct 2022 | CN¥566.1b | CN¥85.6b | CN¥20.5b | 44x | 27.6x | 6.6x |
| Mon, 26 Sep 2022 | CN¥518.1b | CN¥78.2b | CN¥16.9b | 45.6x | 30.6x | 6.6x |
| Wed, 24 Aug 2022 | CN¥608.6b | CN¥73.4b | CN¥17.1b | 60.8x | 35.5x | 8.3x |
| Fri, 22 Jul 2022 | CN¥683.2b | CN¥69.0b | CN¥15.2b | 71.3x | 45x | 9.9x |
Price to Earnings Ratio
45x
Current Industry PE
- Investors are optimistic on the Chinese Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 32.2x which is higher than its 3-year average PE of 28.7x.
- The industry is trading close to its 3-year average PS ratio of 5.3x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have grown 9.2% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.
Industry Comparison
How does Chinese Clinical Research and Equipment compare with similar industries?
| CN Market | 1.80% | |
| Healthcare | 3.10% | |
| Life Sciences | 10.27% | |
| Clinical Research and Equipment | 10.27% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603259 WuXi AppTec | CN¥80.08 | 13.8% +CN¥27.5b | 108.1% | PE17.5x | |
| 300759 Pharmaron Beijing | CN¥26.51 | 6.6% +CN¥2.9b | 36.4% | PE25.1x | |
| 688068 Beijing Hotgen Biotech | CN¥191.50 | 10.3% +CN¥1.6b | 651.0% | PS34.8x | |
| 688131 Shanghai Haoyuan Chemexpress | CN¥58.71 | 11.1% +CN¥1.2b | 172.2% | PE50.2x | |
| 688114 MGI Tech | CN¥64.12 | 3.3% +CN¥841.6m | 48.7% | PS9x |